These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36201473)

  • 21. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF.
    Kozieł M; Teutsch C; Halperin JL; Rothman KJ; Diener HC; Ma CS; Marler S; Lu S; Gurusamy VK; Huisman MV; Lip GYH;
    PLoS One; 2021; 16(4):e0249524. PubMed ID: 33852611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry.
    Ma C; Riou França L; Lu S; Diener HC; Dubner SJ; Halperin JL; Li Q; Paquette M; Teutsch C; Huisman MV; Lip GYH; Rothman KJ;
    J Arrhythm; 2020 Jun; 36(3):408-416. PubMed ID: 32528565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program.
    Mazurek M; Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Zint K; França LR; Lu S; Lip GYH;
    Am J Med; 2018 Aug; 131(8):945-955.e3. PubMed ID: 29654720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.
    Kozieł M; Teutsch C; Bayer V; Lu S; Gurusamy VK; Halperin JL; Rothman KJ; Diener HC; Ma CS; Huisman MV; Lip GYH;
    J Arrhythm; 2021 Aug; 37(4):990-1006. PubMed ID: 34386125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry.
    Boriani G; Proietti M; Laroche C; Fauchier L; Marin F; Nabauer M; Potpara T; Dan GA; Kalarus Z; Diemberger I; Tavazzi L; Maggioni AP; Lip GYH; ;
    Europace; 2018 May; 20(5):747-757. PubMed ID: 29016832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.
    Kozieł M; Mazurek M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Brandes A; Paquette M; Zint K; França LR; Lu S; Bartels DB; Huisman MV; Lip GYH
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32586056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program.
    Boriani G; Huisman MV; Teutsch C; Marler S; França LR; Lu S; Lip GYH;
    Eur J Intern Med; 2020 Oct; 80():35-44. PubMed ID: 32414640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
    Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
    Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Haas S; Camm AJ; Bassand JP; Angchaisuksiri P; Cools F; Corbalan R; Gibbs H; Jacobson B; Koretsune Y; Mantovani LG; Misselwitz F; Panchenko E; Ragy HI; Stepinska J; Turpie AG; Sawhney JP; Steffel J; Lim TW; Pieper KS; Virdone S; Verheugt FW; Kakkar AK;
    Am Heart J; 2019 Jul; 213():35-46. PubMed ID: 31128503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.
    Camm AJ; Accetta G; Ambrosio G; Atar D; Bassand JP; Berge E; Cools F; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Koretsune Y; Mantovani LG; Misselwitz F; Oh S; Turpie AG; Verheugt FW; Kakkar AK;
    Heart; 2017 Feb; 103(4):307-314. PubMed ID: 27647168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.